Have a personal or library account? Click to login
Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status Cover

Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status

Open Access
|Nov 2018

References

  1. Ludwig K, Kornblum HI. Molecular markers in glioma. J Neurooncol 2017; 134: 505-12. doi: 10.1007/s11060-017-2379-y
  2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. doi: 10.1007/s00401-007-0243-4
  3. Siegal T. Clinical impact of molecular biomarkers in gliomas. J Clin Neurosci 2015; 22: 437-44. doi: 10.1016/j.jocn.2014.10.004
  4. Karsy M, Arslan E, Moy F. Current progress on understanding micro-RNAs in glioblastoma multiforme. Genes Cancer 2012; 3: 3-15. doi: 10.1177/1947601912448068
  5. Silber J, James CD, Hodgson JG. microRNAs in gliomas: small regulators of a big problem. Neuromolecular Med 2009; 11: 208-22. doi: 10.1007/s12017-009-8087-9
  6. Zhang Y, Dutta A, Abounader R. The role of microRNAs in glioma initiation and progression. Front Biosci (Landmark Ed) 2012; 17: 700-12. PMID: 22201769
  7. Ilhan-Mutlu A, Wöhrer A, Berghoff AS, Widhalm G, Marosi C, Wagner L, et al. Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. J Neurooncol 2013; 112: 347-54. doi: 10.1007/ s11060-013-1078-6
  8. Yan D, Hao C, Xiao-Feng L, Yu-Chen L, Yu-Bin F, Lei Z. Molecular mechanism of Notch signaling with special emphasis on microRNAs: implications for glioma. J Cell Physiol 2018. doi: 10.1002/jcp.26775
  9. Bucci MK, Maity A, Janss AJ, Belasco JB, Fisher MJ, Tochner ZA, et al. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era. Cancer 2004; 101: 817-24. doi: 10.1002/cncr.20422
  10. Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol 2015; 47: 417-28. doi: 10.3892/ijo.2015.3026
  11. Tezcan G, Tunca B, Bekar A, Preusser M, Berghoff AS, Egeli U, et al. micro-RNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells. Cell Mol Neurobiol 2014; 34: 679-92. doi: 10.1007/s10571-014-0050-0
  12. Chaudhry MA, Sachdeva H, Omaruddin RA. Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways. DNA Cell Biol 2010; 29: 553-61. doi: 10.1089/dna.2009.0978
  13. Lages E, Guttin A, El Atifi M, Ramus C, Ipas H, Dupré I, et al. MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes. PLoS One 2011; 6: e20600. doi: 10.1371/journal.pone.0020600
  14. Gu S, Cheung HH, Lee TL, Lu G, Poon WS, Chan WY. Molecular mechanisms of regulation and action of microRNA-199a in testicular germ cell tumor and glioblastomas. PLoS One 2013; 8: e83980. doi: 10.1371/journal. pone.0083980
  15. Guo Y, Yan K, Fang J, Qu Q, Zhou M, Chen F. Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. J Exp Clin Cancer Res 2013; 32: 41. doi: 10.1186/1756-9966-32-41
  16. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 2007; 87: 392-7. doi: 10.1038/labinvest.3700520
  17. Latham GJ. Normalization of microRNA quantitative RT-PCR data in reduced scale experimental designs. Methods Mol Biol 2010; 667: 19-31. doi: 10.1007/978-1-60761-811-9_2
  18. Wang XR, Luo H, Li HL, Cao L, Wang XF, Yan W, et al. Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN. Neuro Oncol 2013; 15: 1491-501. doi: 10.1093/neuonc/not107
  19. Wu Z, Wang L, Li G, Liu H, Fan F, Li Z, et al. Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma. Mol Cell Biochem 2013; 384: 263-8. doi: 10.1007/s11010-013-1805-5
  20. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009; 13: 39-53. doi: 10.1111/j.1582-4934.2008.00556.x
  21. Wu N, Zhao X, Liu M, Liu H, Yao W, Zhang Y, et al. Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One 2011; 6: e16264. doi: 10.1371/journal.pone.0016264
  22. Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, et al. The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. Tumour Biol 2014; 35: 1459-65. doi: 10.1007/s13277-013-1200-6
  23. Yan S, Han X, Xue H, Zhang P, Guo X, Li T, et al. Let-7f inhibits glioma cell proliferation, migration, and invasion by targeting periostin. J Cell Biochem 2015; 116: 1680-92. doi: 10.1002/jcb.25128
  24. Lee KM, Choi EJ, Kim IA. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 2011; 101: 171-6. doi: 10.1016/j.radonc.2011.05.050
  25. Wang B, Sun F, Dong N, Sun Z, Diao Y, Zheng C, et al. MicroRNA-7 directly targets insulin-like growth factor 1 receptor to inhibit cellular growth and glucose metabolism in gliomas. Diagn Pathol 2014; 9: 211. doi: 10.1186/s13000-014-0211-y
  26. Ben-Hamo R, Efroni S. Gene expression and network-based analysis reveals a novel role for hsa-miR-9 and drug control over the p38 network in glioblastoma multiforme progression. Genome Med 2011; 3: 77. doi: 10.1186/gm293
  27. Chao TF, Xiong HH, Liu W, Chen Y, Zhang JX. MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. J Huazhong Univ Sci Technolog Med Sci 2013; 33: 525-9. doi: 10.1007/s11596-013-1153-4
  28. Deng X, Ma L, Wu M, Zhang G, Jin C, Guo Y, et al. miR-124 radiosensitizes human glioma cells by targeting CDK4. J Neurooncol 2013; 114: 263-74. doi: 10.1007/s11060-013-1179-2
  29. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013; 73: 3913-26. doi: 10.1158/0008-5472.CAN-12-4318
  30. Mizoguchi M, Guan Y, Yoshimoto K, Hata N, Amano T, Nakamizo A, et al. Clinical implications of microRNAs in human glioblastoma. Front Oncol 2013; 3: 19. doi: 10.3389/fonc.2013.00019
  31. Kolenda T, Przybyła W, Teresiak A, Mackiewicz A, Lamperska KM. The mystery of let-7d - a small RNA with great power. Contemp Oncol (Pozn) 2014; 18: 293-301. doi: 10.5114/wo.2014.44467
  32. Kolenda T, Przybyła W, Teresiak A, Mackiewicz A, Lamperska KM. Overexpression of RKIP inhibits cell invasion in glioma cell lines through upregulation of miR-98. Biomed Res Int 2013; 2013: 695179. doi: 10.1155/2013/695179
  33. Xia H, Qi Y, Ng SS, Chen X, Chen S, Fang M, et al. MicroRNA-15b regulates cell cycle progression by targeting cyclins in glioma cells. Biochem Biophys Res Commun 2009; 380: 205-10. doi: 10.1016/j.bbrc.2008.12.169
  34. Sun G, Yan S, Shi L, Wan Z, Jiang N, Li M, et al. Decreased expression of miR-15b in human gliomasi is associated with poor prognosis. Cancer Biother Radiopharm 2015; 30: 169-73. doi: 10.1089/cbr.2014.1757
  35. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
  36. Agarwal S, Suri V, Sharma MC, Sarkar C. Therapy and progression--induced O6-methylguanine-DNA methyltransferase and mismatch repair alterations in recurrent glioblastoma multiforme. Indian J Cancer 2015; 52: 568-73. doi: 10.4103/0019-509x.178403
  37. Smrdel U, Popovic M, Zwitter M, Bostjancic E, Zupan A, Kovac V, et al. Longterm survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. Radiol Oncol 2016; 50: 394-401. doi: 10.1515/raon-2015-0041
  38. Pala A, Schmitz AL, Knoll A, Schneider M, Hlavac M, König R, et al. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients? Clin Neurol Neurosurg 2018; 167: 6-10. doi: 10.1016/j.clineuro.2018.02.003
  39. Wick W, Osswald M, Wick A, Winkler F. Treatment of glioblastoma in adults. Ther Adv Neurol Disord 2018; 11: 1756286418790452. doi: 10.1177/1756286418790452
  40. Visani M, de Biase D, Marucci G, Cerasoli S, Nigrisoli E, Bacchi Reggiani ML, et al. Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I-III. Mol Oncol 2014; 8: 417-30. doi: 10.1016/j.molonc.2013.12.010
DOI: https://doi.org/10.2478/raon-2018-0043 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 422 - 432
Submitted on: Aug 6, 2018
|
Accepted on: Sep 3, 2018
|
Published on: Nov 26, 2018
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2018 Bostjan Matos, Emanuela Bostjancic, Alenka Matjasic, Mara Popovic, Damjan Glavac, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.